Cost-Effectiveness Analysis of Sensor-Augmented Insulin Pump Therapy with Automated Insulin Suspension Versus Standard Insulin Pump Therapy in Patients with Type 1 Diabetes in Sweden

INTRODUCTION: In Sweden an estimated 10,000 people with type 1 diabetes use continuous subcutaneous insulin infusion (CSII). Sensor-augmented pump therapy (SAP) is associated with higher acquisition costs but provides additional clinical benefits (e.g. reduced rate of hypoglycemic events) over and a...

Descripción completa

Detalles Bibliográficos
Autores principales: Jendle, Johan, Smith-Palmer, Jayne, Delbaere, Alexis, de Portu, Simona, Papo, Natalie, Valentine, William, Roze, Stéphane
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5630551/
https://www.ncbi.nlm.nih.gov/pubmed/28871565
http://dx.doi.org/10.1007/s13300-017-0294-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5630551/
https://www.ncbi.nlm.nih.gov/pubmed/28871565
http://dx.doi.org/10.1007/s13300-017-0294-z

Ejemplares similares